Abstract:Yanli Wang, 1 Yan Liu, 1, 2 Yongle Wang, 1, 3 Ping Bai, 1 Madelyn Rose Hallisey, 1 Breanna Lizeth Varela, 1 Anne Siewko, 1 Changning Wang, 1 Yulong Xu 1 1 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; 2 School of Pharmacy, Lanzhou University, Lanzhou, Gansu, 730000, People's Republic of China; 3 School of Pharmacy, Minzu University of China, Beijing, 100081, People's Republic of China Correspondence: Yulong Xu; Changning Wang, Email ; Introduction: Sirtuins (SIRTs) comprise a group of histone deacetylase enzymes crucial for regulating metabolic pathways and contributing significantly to various disease mechanisms. Sirtuin 1 (SIRT1), among the seven known mammalian homologs, is extensively investigated and understood, playing a key role in neurodegenerative disorders and cancer. This study focuses on potential as a therapeutic target for conditions such as Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD). Methods: Utilizing positron emission tomography (PET) as a noninvasive molecular imaging modality, we aimed to expedite the validation of a promising sirtuin 1 inhibitor for clinical trials. However, the absence of a validated sirtuin 1 PET radiotracer impedes clinical translation. We present the development of [ 11 C] 1 , and 11 C-labeled benzoxazine-based derivative, as a lead imaging probe. The radiosynthesis of [ 11 C] 1 resulted in a radiochemical yield of 31 ± 4%. Results: Baseline studies demonstrated that [ 11 C] 1 exhibited excellent blood-brain barrier (BBB) penetration capability, with uniform accumulation throughout various brain regions. Self-blocking studies revealed that introducing an unlabeled compound 1 , effectively blocking sirtuin 1, led to a substantial reduction in whole-brain uptake, emphasizing the in vivo specificity of [ 11 C] 1 for sirtuin 1. Discussion: The development of [ 11 C] 1 provides a valuable tool for noninvasive imaging investigations in rodent models with aberrant sirtuin 1 expression. This novel radiotracer holds promise for advancing our understanding of sirtuin 1's role in disease mechanisms and may facilitate the validation of sirtuin 1 inhibitors in clinical trials. Keywords: sirtuin 1, neuroimaging, benzoxazine-based derivative, blood-brain barrier Sirtuins, as nicotinamide adenine dinucleotide (NAD + )-dependent deacetylases, play a pivotal role in deacetylating diverse protein substrates, including transcription factors and histones. 1 The broad involvement of sirtuins in numerous physiological processes highlights their significant biological relevance. Within the sirtuin family, comprised of seven known members (sirtuin 1–7), each subtype exhibits distinct localization and functions. Notably, sirtuin 1 has garnered substantial attention over the past two decades, primarily due to its association with increased longevity. 2 Extensive evidence suggests that sirtuin 1 plays a role in normal cell development, inflammatory responses, and energy metabolism, making it a potential therapeutic target for addressing age-related diseases, including neurodegenerative disorders and cancer. 3–5 To date, various chemical modulators targeting sirtuin 1 have been developed, encompassing both activators and inhibitors. Sirtuin 1 (SIRT1) activators and inhibitors employ distinct mechanisms to modulate the activity and function of the SIRT1 enzyme. Activators enhance SIRT1's enzymatic activity by interacting with the enzyme, thereby increasing its binding affinity to substrates such as histones and other proteins. Additionally, some activators may induce the upregulation of SIRT1 expression, resulting in elevated enzyme levels. These actions contribute to physiological benefits, including improved metabolic function and potential longevity. Conversely, SIRT1 inhibitors suppress the enzymatic activity of SIRT1 by binding to its catalytic site, preventing the deacetylation of target proteins. The dynamic regulation of the SIRT1 enzyme by both activators and inhibitors influences various cellular pathways and processes in a context-dependent manner. 6 Sirtuin 1 activators, such as resveratrol and SRT1720, have demonstrated protective effects against conditions like diabetes, obesity-induced fatty liver, and insulin resistance. Nonetheless, several limitations hinder the practical applications of these activat -Abstract Truncated-

Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD + Dependent Lysine Deacetylases.

Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy

Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

Thienopyrimidinone Based Sirtuin-2 (Sirt2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket.

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

X-ray Crystal Structure Guided Discovery of New Selective, Substrate-Mimicking Sirtuin 2 Inhibitors That Exhibit Activities Against Non-Small Cell Lung Cancer Cells.

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

Symmetrical 2,7‐disubstituted 9H‐fluoren‐9‐one as a novel and promising scaffold for selective targeting of SIRT2

A Small‐Molecule SIRT2 Inhibitor That Promotes K‐Ras4a Lysine Fatty‐Acylation

Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-n-phenylacetamide Derivatives As New Potent and Selective Human Sirtuin 2 Inhibitors

Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure–Activity Relationship, X-ray Crystal Structure, and Anticancer Activity

Cellular Molecular and Proteomic Profiling Deciphers the SIRT1 Controlled Cell Death Pathways in Esophageal Adenocarcinoma Cells

Targeting Sirtuins for Cancer Therapy: Epigenetics Modifications and Beyond

New ε-N-thioglutaryl-lysine derivatives as SIRT5 inhibitors: Chemical synthesis, kinetic and crystallographic studies

Structure-activity studies of 1,2,4-oxadiazoles for the inhibition of the NAD+ dependent lysine deacylase Sirtuin2

Development and Characterization of a Novel Carbon-11 Labeled Positron Emission Tomography Radiotracer for Neuroimaging of Sirtuin 1 with Benzoxazine-Based Compounds

Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.

Small Molecules as SIRT Modulators

Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis

Molecular Modeling, Chemical Synthesis and Biological Assays